Yutaro Kaneko, Ryo Hatano, Naoto Hirota, Nicolas Isambert, Véronique Trillet-Lenoir, Benoit You, . . . Chikao Morimoto. (2021). Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody. BMC.
Chicago Style (17th ed.) CitationYutaro Kaneko, et al. Serum Soluble CD26/DPP4 Titer Variation Is a Potential Prognostic Biomarker in Cancer Therapy with a Humanized Anti-CD26 Antibody. BMC, 2021.
MLA (9th ed.) CitationYutaro Kaneko, et al. Serum Soluble CD26/DPP4 Titer Variation Is a Potential Prognostic Biomarker in Cancer Therapy with a Humanized Anti-CD26 Antibody. BMC, 2021.
Warning: These citations may not always be 100% accurate.